004310.KS KSC
Hyundai Pharmaceutical Co., Ltd.
1W: -5.9%
1M: +0.6%
3M: +48.9%
YTD: -33.7%
1Y: +117.2%
3Y: +115.3%
5Y: +19.9%
₩8,340.00 ($6.21)
-140.00 (-1.65%)
Weekly Expected Move ±14.4%
₩5935
₩7137
₩8340
₩9543
₩10745
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$166.9B
+6.7% ▲
5Y CAGR: +1.2%
Total Liabilities
$84.8B
+9.7% ▲
5Y CAGR: +4.7%
Shareholders Equity
$82.1B
+3.8% ▲
5Y CAGR: -1.9%
Cash & Investments
$2.5B
-76.3% ▼
5Y CAGR: -34.3%
Total Debt
$50.1B
+4.1% ▲
5Y CAGR: +15.2%
Net Debt
$47.6B
+25.8% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $21.6B | $30.3B | $16.2B | $10.3B | $2.5B |
| Short-Term Investments | $580M | $4.3B | $2.4B | $272M | $0 |
| Cash & ST Investments | $22.2B | $34.5B | $18.6B | $10.5B | $2.5B |
| Net Receivables | $40.3B | $42.5B | $39.0B | $38.7B | $44.7B |
| Inventory | $22.0B | $24.1B | $27.0B | $29.1B | $32.6B |
| Other Current Assets | $354M | $42.6B | $531M | $853M | $1.0B |
| Total Current Assets | $84.9B | $101.6B | $85.5B | $79.6B | $80.8B |
| Property, Plant & Equip. | $29.3B | $28.6B | $29.4B | $37.4B | $39.2B |
| Goodwill & Intangibles | $13.5B | $17.3B | $5.6B | $6.7B | $7.3B |
| Long-Term Investments | $10.3B | $6.8B | $7.9B | $9.7B | $29.7B |
| Other Non-Current Assets | $19.8B | $23.3B | $23.1B | $18.3B | $1.8B |
| Total Non-Current Assets | $79.0B | $79.5B | $69.2B | $76.8B | $86.1B |
| Total Assets | $163.9B | $181.2B | $154.6B | $156.4B | $166.9B |
| — Liabilities — | |||||
| Accounts Payable | $16.6B | $18.1B | $11.8B | $10.1B | $13.6B |
| Short-Term Debt | $14.0B | $29.0B | $38.0B | $33.0B | $44.1B |
| Deferred Revenue | $14.8B | $20.0B | $14.9B | $0 | $4.9B |
| Other Current Liabilities | $9.1B | $25.6B | $17M | $8.8B | $6.8B |
| Total Current Liabilities | $45.9B | $80.7B | $65.3B | $58.7B | $71.4B |
| Long-Term Debt | $15.0B | $10.0B | $0 | $14.7B | $5.8B |
| Other Non-Current Liab. | $6.7B | $3.5B | $342M | $3.3B | $1.2B |
| Total Non-Current Liabilities | $31.4B | $13.9B | $4.6B | $22.3B | $13.4B |
| Total Liabilities | $77.3B | $94.6B | $70.0B | $77.3B | $84.8B |
| — Equity — | |||||
| Common Stock | $16.0B | $16.0B | $16.0B | $16.0B | $16.0B |
| Retained Earnings | $48.4B | $49.6B | $52.9B | $2.7B | $6.0B |
| Accumulated OCI | $67.4B | $64.3B | $62.8B | $62.2B | $61.9B |
| Total Stockholders Equity | $86.6B | $86.6B | $84.7B | $79.1B | $82.1B |
| Total Liabilities & Equity | $163.9B | $181.2B | $154.6B | $156.4B | $166.9B |
| — Key Metrics — | |||||
| Total Debt | $29.8B | $39.4B | $39.2B | $48.1B | $50.1B |
| Net Debt | $8.2B | $9.2B | $23.0B | $37.8B | $47.6B |
| Total Investments | $10.9B | $11.1B | $10.4B | $10.0B | $29.7B |